Alzheimer disease update: New targets, new options

Drug Benefit Trends

Volumn 17, Issue 2, 2005, Pages 83-95

  Reynolds, Jessica ^a   Mintzer, Jacobo ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acetylcholine; Alzheimer disease; Memantine; NSAIDs; Statins

Indexed keywords

ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ANTIINFLAMMATORY AGENT; ASCORBIC ACID; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYPOCHOLESTEROLEMIC AGENT; MEMANTINE; NOOTROPIC AGENT; RIVASTIGMINE; TACRINE;

ACETYLCHOLINE BRAIN LEVEL; AGE DISTRIBUTION; ALZHEIMER DISEASE; CAREGIVER; DETERIORATION; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG EFFICACY; EMOTIONAL STRESS; FAMILY; FEVER; FINANCIAL MANAGEMENT; GAIT DISORDER; HUMAN; IMMUNIZATION; REVIEW; SIDE EFFECT; TREATMENT PLANNING;

EID: 14144253727     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003; 60:1119-1122.
2. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84:1261-1264.
3. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, "Über eine eigenartige Erkankung der Hirnrinde." Clin Anat. 1995;8: 429-431.
4. Alzheimer's Disease Education & Referral Center. General information. Available at: www.alzheimers.org/generalinfo.htm. Accessed January 19, 2005.
5. Cotran RS, Kumar V, Collins T, eds. Robbins Pathologic Basis of Disease. 6th ed. Philadelphia: WB Saunders Company; 1999:1330-1334.
6. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 200021:383421.
7. Tenner AJ. Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging. 2001;22:849-861.
8. Breitner JC. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging. 1996;17:789-794.
9. Geula C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. Neurology. 1998;51 (suppl 1)518-829.
10. Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol. 2003;2:215-20.
11. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med. 2000;6:916-919.
12. Janus C, Pearson J, McLaurin J, et al. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979-982.
13. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzhiemer's disease [published correction appears in Nature. 2001;412:660]. Nature. 2000;408:982-985.
14. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzhiemer's disease [published correction appears in Nature. 2001;412:660]. Nature. 2000;408:982-985.
15. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med. 2003;9:448-452.
16. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator- activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272:3406-3410.
17. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
18. in t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001; 345:1515-1521.
19. 2 receptor antagonists: the Cache County Study. Neurology. 2002;59:880-886.
20. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62:66-71.
21. Aisen PS, Davis KL, Berg JO, et al. A randomized controlled trial of prednisone in Alzheimer 's disease: Alzheimer's Disease Cooperative Study. Neurology. 2000;54:588-593.
22. Aisen PS, Schafer KA, Grundman M, et al, for the Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826.
23. Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 1999;53:197-201.
24. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxycholoroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study [published correction appears in Lancet. 2001;358:1188]. Lancet. 2001;358:455-460.
25. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxycholoroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study [published correction appears in Lancet. 2001;358:1188]. Lancet. 2001;358:455-460.
26. National Institutes of Health. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. Available at: www.nih.gov/news/pr/dec2004/od-20.htm. Accessed January 13, 2005.
27. National Institutes of Health. NIH halts use of COX-2 inhibitors in large cancer prevention trial. Available at: www.nih.gov/news/pr/dec2004/od-17.htm. Accessed January 13, 2005.
28. Solomon DG, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109:2068-2073.
29. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709-1711.
30. Behl C, Davies JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid β protein activity. Cell. 1994;77:817-827.
31. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol. 1999;57:301-323.
32. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002;287:3223-3229.
33. Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002;2873230-3237.
34. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004;61:82-88.
35. Lushinger JA, Tang MX, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol. 2003;60:203-208.
36. Laurin D, Masaki KH, Foley DJ, et al.Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol. 2004;159:959-967.
37. Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
38. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
39. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460-6464.
40. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
41. Haley RW, Dietschy JM. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol. 2000; 57:1410-1412.
42. Sparks DL, Sabbagh MN, Connor DJ, et al. Benefits of atorvastatin in subject with Alzheimer's disease. Presented at: American Heart Association Scientific Sessions; November 7-10, 2004; New Orleans.
43. Ishii K, Tokuda T, Matsushima T, et al. Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans. Neurosci Lett. 2003;350:161-164.
44. Mehta PD, Pirttila T, Mehta SP, et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57:100-105.
45. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322:1447-1451.
46. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149-155.
47. Skoog I, Lernfelt B, Landahl S, et al. 15-Year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-1145.
48. Sparks DL, Scheff SW, Liu H, et al. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci. 1995;131:162-169.
49. Fujishima M, Kiyohara Y. Incidence and risk factors of dementia in a defined elderly Japanese population: the Hisayama study. Ann N Y Acad Sci. 2002;977:1-8.
50. Posner HB, Tang MX, Luchsinger J, et al. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology. 2002;58:1175-1181.
51. in't Veld BA, Ruitenberg A, Hofman A, et al. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 2001;22:407-412.
52. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch Intern Med. 2002;162:2046-2052.
53. Arvanitakis Z, Wison RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004; 61:661-666.
54. Knopman D, Boland LL, Mosley T, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42-48.
55. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Aβ peptide: the many roads to perdition. Neuron. 2004;43:605-608.
56. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998;19:608-624.
57. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery, a neuropsychological test for severely demented patients. Arch Neurol. 1994;51:41-45.
58. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
59. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39.
60. Schneider LS, Olin JT, Doody RS, et al, for the Alzheimer's Disease Cooperative Study. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997;11 (suppl 2):S22-S32.
61. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of prclinical data. Neuropharmacology. 1999;38:735-767.
62. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;84:1333-1341.
63. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324.
64. Forest Laboratories. FDA accepts supplemental new drug application filing to expand Namenda's indication to include treatment of mild Alzheimer's disease. Available at: http://ir.frx.com/phoenix.zhtml?c=83198&p= irolnewsArticle&ID=643920&highlight. Accessed December 29, 2004.
65. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 2001;15:169-173.